CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.56B, above the global median of $1.18B
- FinancialsAltman Z-Score -0.41: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.56BUSDvs all stocks (USD)
Revenue (TTM)
815.05MUSDvs all stocks (USD)
Profit Margin
-13.49%vs Medical Devices peers
Beta
0.8490xvs all stocks
52-Week Change
-31.39%vs all stocks
Market Capitalization
1.56BUSDvs all stocks (USD)
Enterprise Value
2.07BUSDvs all stocks (USD)
Forward P/E
16.86xvs Medical Devices peers
Price to Sales (TTM)
1.92xvs Medical Devices peers
Enterprise to Revenue
2.54xvs Medical Devices peers
Enterprise to EBITDA
54.01xvs Medical Devices peers
Gross Margin
72.17%vs Medical Devices peers
Profit Margin
-13.49%vs Medical Devices peers
Operating Margin
-0.93%vs Medical Devices peers
Return on Assets (TTM)
-3.07%vs Medical Devices peers
Revenue (TTM)
815.05MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.31USDUpdated Sep 26, 2026Quarterly Revenue Growth
15.10%vs Medical Devices peers
Gross Profit (TTM)
577.36MUSDvs all stocks (USD)
EBITDA (TTM)
26.20MUSDvs all stocks (USD)
Net Income (TTM)
-109.99MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.07%vs Medical Devices peers
Operating Cash Flow (TTM)
56.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
48.31MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
764.15MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
232.27MUSDFY2025 · Dec 31, 2025Gross Profit
531.89MUSDFY2025 · Dec 31, 2025Operating Income
-57.97MUSDvs all stocks (USD)
Pre-tax Income
-143.40MUSDFY2025 · Dec 31, 2025Income Tax Expense
-45.00KUSDFY2025 · Dec 31, 2025Net Income
-143.36MUSDFY2025 · Dec 31, 2025EBIT
-97.48MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
26.20MUSDFY2025 · Dec 31, 2025Research & Development
76.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
498.53MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.92MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.9600USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.9600USDFY2025 · Dec 31, 2025Basic Shares Outstanding
150.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
150.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-143.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-1.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-44.26MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
160.81MUSDFY2025 · Dec 31, 2025Income Tax Paid
389.00KUSDFY2025 · Dec 31, 2025Interest Paid
23.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-143.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
82.56MUSDFY2025 · Dec 31, 2025Stock-based Compensation
73.72MUSDFY2025 · Dec 31, 2025Other Non-cash Items
30.90MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-21.88MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-11.16MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-42.45MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-7.19MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-3.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-770.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-46.23MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
407.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-332.19MUSDFY2025 · Dec 31, 2025Other Financing Charges
-45.31MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
154.49MSharesUpdated Sep 26, 2026Float Shares
122.06MSharesUpdated Sep 26, 2026Shares Short
14.43MSharesUpdated Sep 26, 2026Short Ratio
7.07daysvs all stocks
Short % of Shares Outstanding
10.78%vs all stocks
% Held by Insiders
20.46%vs all stocks
% Held by Institutions
76.46%vs all stocks
Total Cash (MRQ)
118.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7680USDUpdated Sep 26, 2026Total Debt (MRQ)
604.02MUSDvs all stocks (USD)
Current Ratio (MRQ)
1.89xvs Medical Devices peers
Book Value per Share (MRQ)
-0.0790USDUpdated Sep 26, 2026Total Assets
791.21MUSDvs all stocks (USD)
Total Current Assets
450.88MUSDFY2025 · Dec 31, 2025Total Liabilities
778.78MUSDFY2025 · Dec 31, 2025Total Non-current Assets
340.33MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
559.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
219.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
160.81MUSDFY2025 · Dec 31, 2025Accounts Receivable
97.30MUSDFY2025 · Dec 31, 2025Inventory
169.44MUSDFY2025 · Dec 31, 2025Accounts Payable
40.89MUSDFY2025 · Dec 31, 2025Short-term Debt
70.82MUSDFY2025 · Dec 31, 2025Deferred Revenue
10.44MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.94MUSDFY2025 · Dec 31, 2025Long-term Debt
525.27MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.12MUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.42BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
12.43MUSDvs all stocks (USD)
Treasury Stock
25.10MUSDFY2025 · Dec 31, 202552-Week Low
6.82USDUpdated Sep 26, 202652-Week High
23.29USDUpdated Sep 26, 202652-Week Change
-31.39%vs all stocks
Beta
0.8490xvs all stocks
50-Day MA
9.48USDUpdated Sep 26, 2026200-Day MA
11.83USDUpdated Sep 26, 2026Avg 10-Day Volume
2.45MSharesUpdated Sep 26, 2026Avg 30-Day Volume
2.07MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.7100USDUpdated Sep 26, 2026Other Income / Expense
-39.52MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Elevated Leverage on Three Denominators
Debt sits high against its equity, its assets, and its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: -0.13
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.89Altman Z-Score: -0.41
Financial Health
Altman Z-Score -0.41: distress zoneCritical
Altman Z-Score: -0.41
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.56B, above the global median of $1.18BNotable
Market cap (USD): 1,563,044,889Global Median: 1,180,223,658.953
Revenue is $815.05M, above the global median of $548.88MNotable
Revenue (USD): 815,052,032Global Median: 548,883,780.48
Levered free cash flow is $48.31M, above the global median of $18.73MNotable
Levered free cash flow (USD): 48,314,752Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Zamil Industrial Investment Co.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Cheng Uei Precision Industry Co. Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone
Zhanjiang Guolian Aquatic Products Co., Ltd.
2 interpretationsElevated Leverage on Three DenominatorsWithin or Near the Altman Distress Zone